Skip to main content

Pluvicto FDA Approval History

Last updated by Judith Stewart, BPharm on April 5, 2022.

FDA Approved: Yes (First approved March 23, 2022)
Brand name: Pluvicto
Generic name: lutetium lu 177 vipivotide tetraxetan
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Prostate Cancer

Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

Development timeline for Pluvicto

Mar 23, 2022Approval FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.